Recently, the three-day CPHI&PMEC China 2023 were held at the Shanghai New International Expo Center. Hetero Labs Limited, the premium partner of Shenzhen Beimei Pharmaceutical Co., Ltd., participated in the exhibition and awarded Beimei Pharmaceutical The Most Valuable Partner Collaboration Award.

(BeiMei Pharma's Chairman and CEO, Claire Wu, receives the trophy)

Beimei Pharmaceutical has developed a deep cooperation with Hetero Labs Limited.

奥维平® (Oseltamivir Phosphate for Suspension) is the first product approved by China NMPA under the cooperation between Beimei Pharmaceutical and Hetero. Beimei Pharmaceutical achieved an outstanding performance from its registration filing, market access to the bidding of national centralized drug procurement. Notably, in March of 2023, 奥维平® won the highest bid in the eighth batch of the national centralized drug procurement.

The Most Valuable Partner Collaboration Award shows that Hetero acknowledges Beimei Pharmaceutical’s commercialization and operational performance and appreciates the mutual trust during the cooperation. In the future, to create a win-win situation, Beimei Pharmaceutical will work closer with Hetero in field of pediatric drugs to meet the unmet needs of pediatrics. 

About Hetero

Founded in 1993, Hetero is India's largest private pharmaceutical company, a leading generic drug manufacturer in India, and one of the world's largest producers of antiretroviral drugs for HIV/AIDS treatment. Committed to the development, production, and marketing of high-quality chemical and biological drugs across various therapeutic areas.

After 30 years of excellence, Hetero has become one of the world's largest producers of ARV APIs & FDFs, with more than 300 APIs and more than 200 FDFs. The company has a network of operations in more than 140 countries and employs more than 22,000 people worldwide. It is globally renowned for its strengths in the development, manufacturing and commercialization of a wide range of products.

About Shenzhen Beimei Pharmaceutical Co., Ltd.

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen, China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields.

Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr. Reddy, LTS, MedPharma, Synthon, NTC, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated.

For more information, please visit our website at http://www.beimeiyaoye.com